In this latter scenario, a 25% backlog would result in a further 401 additional lives and 7332 life–years lost due to diagnostic delays, increasing to 811 and 14,873, respectively, with a backlog of 50%, and 1231 and 22,635, respectively, under a 75% backlog.

Finally, the SPARTAN investigators reported that after a median follow-up of 52 months, the risk for death was a significant 22% lower for the 806 men treated with apalutamide 240 mg/day plus ADT than for the 401 who received placebo plus ADT, with respective median OS times of 73.9 and 59.9 months.

Their multicenter postmarketing surveillance study included 401 French men (median age 70 years) with mCRPC who began treatment with cabazitaxel between 2013 and 2015.

At a median follow-up of 21.2 months, 49% of 401 patients randomly assigned to receive up to six intravenous injections of radium-223 (55 kBq/kg) with concurrent oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily had experienced at least one symptomatic skeletal event or died.

Of 401 interventional prostate cancer trials, 25.2% used unadjusted serum creatinine levels alone to determine eligibility, even though Black patients tend to have higher values for any given functional status.

And the median metastasis-free survival (MFS) time was 40.5 months for the 806 patients who were randomly assigned to the apalutamide group and 16.2 months for their 401 counterparts in the placebo group.